{"id":"propranolol-pyridostigmine","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Increased salivation"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination leverages propranolol's sympathetic nervous system suppression to manage cardiovascular symptoms, while pyridostigmine enhances parasympathetic signaling by preventing acetylcholine breakdown. Together, they address both adrenergic hyperactivity and neuromuscular dysfunction, commonly used in conditions like myasthenia gravis with concurrent cardiac symptoms or thyroid storm management.","oneSentence":"Propranolol blocks beta-adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:09.850Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myasthenia gravis with cardiac manifestations"},{"name":"Thyroid storm with neuromuscular complications"}]},"trialDetails":[{"nctId":"NCT02171988","phase":"PHASE4","title":"Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-03","conditions":"Postural Orthostatic Tachycardia Syndrome","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Propranolol+pyridostigmine","genericName":"Propranolol+pyridostigmine","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Propranolol blocks beta-adrenergic receptors to reduce heart rate and blood pressure, while pyridostigmine inhibits acetylcholinesterase to increase acetylcholine levels and enhance neuromuscular transmission. Used for Myasthenia gravis with cardiac manifestations, Thyroid storm with neuromuscular complications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}